help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seiden, M. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seiden, M. V.
The Oncologist, Vol. 6, No. 4, 327-332, August 2001
© 2001 AlphaMed Press

ASCO 2001: CRITICAL COMMENTARIES PART 1

Ovarian Cancer

Michael V. Seiden

Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA

Correspondence: Michael V. Seiden, M.D., Ph.D., Massachusetts General Hospital, Cox 640, 100 Blossom Street, Boston, Massachusetts 02114, USA. Telephone: 617-724-3123; Fax: 617-724-3166; e-mail: Mseiden{at}partners.org

Ovarian cancer remains the most lethal gynecologic malignancy in women in the United States. Studies from this year's American Society of Clinical Oncology more clearly defined the role of chemotherapy in women with early stage disease and now suggest that essentially all women with invasive disease should receive chemotherapy that contains carboplatin. Studies in women with advanced disease continue to support the use of carboplatin and paclitaxel in the treatment of women with newly diagnosed disease although early data suggest that carboplatin and docetaxel might be an acceptable alternative. Platinum-resistant disease remains a therapeutic challenge. Small molecules that inhibit the function of the epidermal growth factor receptor, such as OSI-774, and novel classes of chemotherapeutic agents, including the acylfulvene MGI-114 and epothilone B and its analogue, BMS247550, all warrant further study in this disease.

Key Words. Ovarian cancer • Treatment • ASCO




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
H. Devalapally, Z. Duan, M. V. Seiden, and M. M. Amiji
Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles
Clin. Cancer Res., May 15, 2008; 14(10): 3193 - 3203.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. J. Herzog
Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression?
Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Wang, T. Wiltshire, Y. Wang, C. Mikell, J. Burks, C. Cunningham, E. S. Van Laar, S. J. Waters, E. Reed, and W. Wang
ATM-dependent CHK2 Activation Induced by Anticancer Agent, Irofulven
J. Biol. Chem., September 17, 2004; 279(38): 39584 - 39592.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. J. Dunton
Management of Treatment-Related Toxicity in Advanced Ovarian Cancer
Oncologist, October 1, 2002; 7(90005): 11 - 19.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 2001 by AlphaMed Press.